Skip to search formSkip to main contentSkip to account menu

Delavirdine Mesylate

Known as: Delavirdine Mesylate [Chemical/Ingredient], Mesylate, Delavirdine 
A mesylate salt form of delavirdine, a synthetic, non-nucleoside reverse transcriptase inhibitor. In combination with other anti-retroviral drugs… 
National Institutes of Health

Related topics

Related topics

17 relations
Acquired Immunodeficiency SyndromeAlprazolamAstemizoleCisapride

Broader (3)

DelavirdineIndolesPiperazines

Narrower (2)

RescriptorU-90152

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Determination of the Composition of Delavirdine Mesylate Polymorph and Pseudopolymorph Mixtures Using 13C CP/MAS NMR
  • P. Gao
  • Pharmaceutical Research
  • 2004
  • Corpus ID: 6122113
AbstractPurpose. The application of solid-state nuclear magnetic resonance for the quantitation of relative amounts of… 
Review
2002
Review
2002
Rifampin and rifabutin drug interactions: an update.
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes. A few examples of well-documented clinically significant… 
1999
1999
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3…
To evaluate the antiretroviral activity of delavirdine mesylate, a non-nucleoside reverse transcriptase inhibitor of HIV-1, we… 
Highly Cited
1998
Highly Cited
1998
Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.
Administration of delavirdine, an HIV-1 reverse transcriptase inhibitor, to rats or monkeys resulted in apparent loss of hepatic… 
1998
1998
Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
The potential pharmacokinetic drug-drug interaction between delavirdine, a nonnucleoside analogue reverse transcriptase inhibitor… 
Highly Cited
1997
Highly Cited
1997
Steady‐state pharmacokinetics of delavirdine in HIV‐positive patients: Effect on erythromycin breath test
1997
1997
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection
Delavirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1… 
Highly Cited
1997
Highly Cited
1997
Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
Review
1996
Review
1996
Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
  • W. Freimuth
  • Advances in experimental medicine and biology
  • 1996
  • Corpus ID: 44512677
In summary, DLV has been well-tolerated in > 1,000 HIV-1 infected patients. Skin rash is the most prevalent medical event… 
Highly Cited
1996
Highly Cited
1996
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
Delavirdine mesylate (DLV) is a potent nonnucleoside reverse transcriptase inhibitor with activity specific for human… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License